Nektar Therapeutics

Sümbol: 0UNL.L

LSE

1.65

USD

Turuhind täna

-1.1419
P/E suhe
0.0069
PEG suhe
302.98M
MRK Cap
0.00%
DIV tootlus

Nektar Therapeutics (0UNL-L) Finantsaruanded

Q: Mis on Nektar Therapeutics (0UNL.L) koguvara?

Nektar Therapeutics (0UNL.L) koguvara on .

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Nektar Therapeutics (0UNL.L) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Nektar Therapeutics fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012
balance-sheet.row.cash-and-short-term-investments	303.6	505	734	1061.9	1324.9	1335.3	296.1	389.1	308.9	237.8	237	277.2
balance-sheet.row.short-term-investments	283.5	438.1	719.7	872.6	1235.5	1140.4	291.4	329.5	253.4	225.5	198	251.8
balance-sheet.row.net-receivables	2.3	6	23.9	44	36.8	43.2	5	15.7	19.9	3.6	2.2	5.8
balance-sheet.row.inventory	16.1	19.2	15.8	19.2	44.5	11.4	10.7	11.1	11.3	13	13.5	18.3
balance-sheet.row.other-current-assets	8.7	15.8	21.9	12.9	15.4	47.7	14.9	10.1	9.8	33.8	5.2	13.4
balance-sheet.row.total-current-assets	330.7	546	795.6	1138	1421.5	1437.7	326.8	426	350.1	288.2	257.9	314.6
balance-sheet.row.property-plant-equipment-net	36.9	85.9	177.5	186.1	199.2	48.9	47.5	65.6	71.3	70.4	67	72.2
balance-sheet.row.goodwill	0	76.5	76.5	76.5	76.5	76.5	76.5	76.5	76.5	76.5	76.5	76.5
balance-sheet.row.intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	0	76.5	76.5	76.5	76.5	76.5	76.5	76.5	76.5	76.5	76.5	76.5
balance-sheet.row.long-term-investments	25.8	0	64.8	136.7	279.1	582.9	57.1	0	0	0	0	0
balance-sheet.row.tax-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	4.6	2.2	2.7	1.5	1	-708.2	-181.1	-142.1	-147.8	-146.9	-143.5	-148.7
balance-sheet.row.total-non-current-assets	67.3	164.6	321.6	400.8	555.8	708.2	181.1	142.1	147.8	146.9	143.5	148.7
balance-sheet.row.other-assets	0	0	0	0	0	4.2	1	0.8	0.8	6.6	33.2	34.4
balance-sheet.row.total-assets	398	710.6	1117.2	1538.8	1977.4	2150.2	508.9	568.9	498.6	441.6	434.5	497.8
balance-sheet.row.account-payables	9.8	13	9.7	22.1	19.2	5.9	4.8	2.8	2.4	2.7	9.1	2.9
balance-sheet.row.short-term-debt	19.3	18.7	17.4	13.9	261.2	0	0	0	0	0	0	0
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	112.6	126.5	148.1	170.1	47	246.9	245.2	243.5	241.7	125	125	125
Deferred Revenue Non Current	0	0	0	2.5	2.6	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	22.2	36.6	58	79.6	67.9	76.1	51.4	69.4	58.9	61.3	89.1	75.7
balance-sheet.row.total-non-current-liabilities	215.8	275.8	352.5	345.7	218.1	246.9	245.2	243.5	241.7	125	125	125
balance-sheet.row.other-liabilities	0	0	0	0	0	103.6	119.7	165.1	189.3	216.2	301.2	247.2
balance-sheet.row.capital-lease-obligations	98.5	112.8	125.7	136.4	142.7	0	0	0	0	0	0	0
balance-sheet.row.total-liab	267	344	437.7	461.5	572	432.6	421	480.7	492.2	405.3	524.4	450.8
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-3477.2	-3201.2	-2833	-2309.2	-1864.7	-1424.1	-2117.9	-2021	-1867.5	-1786.3	-1732.4	-1570.4
balance-sheet.row.accumulated-other-comprehensive-income-loss	0.1	-6.9	-4.2	-2.3	-1	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	3608.1	3574.7	3516.6	3388.7	3271.1	3141.6	2205.8	2109.1	1873.9	1822.6	1642.5	1617.4
balance-sheet.row.total-stockholders-equity	131	366.6	679.5	1077.3	1405.4	1717.6	87.8	88.1	6.4	36.3	-89.9	47
balance-sheet.row.total-liabilities-and-stockholders-equity	398	710.6	1117.2	1538.8	1977.4	0	0	0	0	0	0	0
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	131	366.6	679.5	1077.3	1405.4	1717.6	87.8	88.1	6.4	36.3	-89.9	47
balance-sheet.row.total-liabilities-and-total-equity	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	309.3	438.1	784.5	1009.2	1514.6	1723.3	348.5	329.5	253.4	225.5	198	251.8
balance-sheet.row.total-debt	230.4	258	291.3	320.4	450.9	0	0	0	0	0	0	0
balance-sheet.row.net-debt	210.2	191.1	277	131	361.5	-194.9	-4.8	-59.6	-55.6	-12.4	-39.1	-25.4

Rahavoogude aruanne

Nektar Therapeutics finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012
cash-flows.row.net-income	-276.1	-368.2	-523.8	-444.4	-440.7	681.3	-96.7	-153.5	-81.2	-53.9	-162	-171.9
cash-flows.row.depreciation-and-amortization	7.8	12.2	13	12.5	11	10.9	14.7	15.4	12.9	12.9	14.3	14.5
cash-flows.row.deferred-income-tax	-0.1	2.7	-106.6	-93.5	-104.9	-61.9	-47.7	-30.4	-4.9	-16.1	-26.1	-9.7
cash-flows.row.stock-based-compensation	-13	57.3	94.7	94.3	99.8	88.1	36.6	25.9	19.7	17	17.7	16.2
cash-flows.row.change-in-working-capital	-19.8	0.5	-23.1	16.7	21.7	-26.2	11	4.5	-14.7	-0.9	8.4	-6.5
cash-flows.row.account-receivables	4.8	16.5	12.4	1.9	6.4	-25.5	10.7	4.3	-16.3	-1.4	3.6	-0.9
cash-flows.row.inventory	0.7	-3.4	-0.5	-2.6	-1.3	-0.7	0.4	0.2	1.6	0.5	4.8	-5.6
cash-flows.row.account-payables	-2.9	3.1	-11.7	2.4	13	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	-22.4	-15.7	-23.3	15	3.6	0	0	0	0	0	0	0
cash-flows.row.other-non-cash-items	108.6	-8.5	133.1	101.2	84.4	26	-46.1	-9.2	-9.7	-117.2	83.1	17.9
cash-flows.row.net-cash-provided-by-operating-activities	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-0.9	-5.7	-15	-7.3	-26.3	-14.2	-9.7	-6.4	-11.2	-10	-4.1	-10.6
cash-flows.row.acquisitions-net	1.2	13.2	-217.8	-503.5	-233.2	0	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	-511.7	-467.9	-960.7	-987.5	-1380.9	0	0	0	0	0	0	0
cash-flows.row.sales-maturities-of-investments	650.9	826.2	1178.5	1491	1614	0	0	0	0	0	0	0
cash-flows.row.other-investing-activites	0	0	217.8	503.5	233.2	-1365.7	-19.1	-76	-3.1	-27.6	54	123.6
cash-flows.row.net-cash-used-for-investing-activites	139.6	365.8	202.8	496.2	206.9	-1379.9	-28.8	-82.4	-14.3	-37.6	49.9	113
cash-flows.row.debt-repayment	0	0	0	-103.8	0	0	-5.1	-5.9	-130.2	-3.5	-3	-174.8
cash-flows.row.common-stock-issued	0	0.8	33.2	23.4	23.4	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	0	0.8	3	-80.4	23.4	852	59.5	209.6	261	156.5	5.2	201.6
cash-flows.row.net-cash-used-provided-by-financing-activities	0	1.5	36.2	-80.4	23.4	852	54.4	203.6	130.8	153	2.2	26.8
cash-flows.row.effect-of-forex-changes-on-cash	6.3	-0.3	-0.1	0	-0.1	-0.1	0	-0.1	-0.2	-0.1	0	0.1
cash-flows.row.net-change-in-cash	-46.7	52.5	-175.1	99.9	-105.5	190.1	-54.9	4.1	43.2	-26.7	13.6	10.1
cash-flows.row.cash-at-end-of-period	20.2	66.8	14.3	189.3	89.4	194.9	4.8	59.6	55.6	12.4	39.1	25.4
cash-flows.row.cash-at-beginning-of-period	66.8	14.3	189.3	89.4	194.9	4.8	59.6	55.6	12.4	39.1	25.4	15.3
cash-flows.row.operating-cash-flow	-192.6	-304	-412.7	-313.3	-328.7	718.2	-80.4	-117	-73.1	-142	-38.5	-129.8
cash-flows.row.capital-expenditure	-0.9	-5.7	-15	-7.3	-26.3	-14.2	-9.7	-6.4	-11.2	-10	-4.1	-10.6
cash-flows.row.free-cash-flow	-193.5	-309.7	-427.6	-320.5	-355	704	-90.1	-123.4	-84.3	-152	-42.6	-140.3

Kasumiaruande rida

Nektar Therapeutics tulud muutusid võrreldes eelmise perioodiga NaN%. 0UNL.L brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012
income-statement-row.row.total-revenue	90.1	92.1	101.9	152.9	114.6	1193.3	307.7	165.4	230.8	200.7	148.9	81.2
income-statement-row.row.cost-of-revenue	36.6	29.1	34.7	28.7	29.5	24.4	30.5	30.2	34.1	28.5	38.5	30.4
income-statement-row.row.gross-profit	53.5	62.9	67.2	124.2	85.1	1168.9	277.2	135.2	196.7	172.2	110.4	50.8
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.operating-expenses	190.9	303.2	513.3	504.1	525.1	481	336.8	248.1	240.1	188.7	230.5	192
income-statement-row.row.cost-and-expenses	227.5	332.3	548	532.8	554.7	505.4	367.4	278.3	274.2	217.2	269.1	222.4
income-statement-row.row.interest-income	19	22.2	44.7	18.8	0	5.2	36.4	39.8	37.2	37.9	39.6	30.2
income-statement-row.row.interest-expense	25.3	28.9	47.3	37.1	46.4	0	0	0	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-138.8	-124.7	-77.2	-64	0	-5.2	-52.4	-39.8	-51.3	-37.9	-39.6	-31.9
income-statement-row.row.ebitda-ratio-caps	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.total-operating-expenses	-138.8	-124.7	-77.2	-64	0	-5.2	-52.4	-39.8	-51.3	-37.9	-39.6	-31.9
income-statement-row.row.interest-expense	25.3	28.9	47.3	37.1	46.4	0	0	0	0	0	0	0
income-statement-row.row.depreciation-and-amortization	7.8	12.2	13	12.5	11	10.9	14.7	15.4	12.9	12.9	14.3	14.5
income-statement-row.row.ebitda-caps	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-137.4	-240.2	-446.1	-379.9	-440	687.9	-43.7	-112.9	-29.4	-16.5	-120.1	-139.5
income-statement-row.row.income-before-tax	-276.3	-365	-523.3	-443.9	-440.1	682.7	-96.1	-152.6	-80.7	-54.4	-159.8	-171.4
income-statement-row.row.income-tax-expense	-0.2	3.2	0.6	0.5	0.6	1.4	0.6	0.9	0.5	0.5	2.2	0.4
income-statement-row.row.net-income	-276.1	-368.2	-523.8	-444.4	-440.7	681.3	-96.7	-153.5	-81.2	-53.9	-162	-171.9